Oncopeptides | Sustainability Performance
Oncopeptides AB focuses on developing peptide-targeted therapies for treating cancer, primarily dedicated to researching and producing innovative medical solutions for oncological disorders.
2003
Sweden
51 - 200 employees
Pharmaceuticals
$1M - 10M in revenue
Not profitable
Submit or report inaccurate dataDownload Company InsightsⓘBy downloading this report, you'll receive the most insightful and detailed analysis of the company's sustainability performance, compared to its peers. It includes key industry trends, carbon and energy intensity, nature impact, social metrics, and an in-depth look at key risks and controversies.
Sustainability Ranking & Industry Benchmark
#9669
Overallⓘ#437
in Swedenⓘ#232
in PharmaceuticalsⓘSustainability Maturity
ⓘSustainability Intent
ⓘOverview
Financial Data
Business performanceCapital & innovationAnalyst projections
Controversy level
- Oncopeptides voluntarily withdrew its melflufen cancer drug from the US market in 2021 after a confirmatory trial showed an overall survival detriment.
Sustainability employees
ⓘWe follow the strictest rules to ensure compliance with all the relevant data protection laws, including GDPR. Click here for our Privacy Policy.Total sustainability employees
2-3
ⓘThis value represents the estimated number of employees in a company with sustainability-related roles or job titles, as determined by Illuminem using publicly available data.